HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Auranofin (Ridaura)

An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.

Also Known As:

Ridaura; Crisinor; Recordati Brand of Auranofin; Ridauran; Robapharm Brand of Auranofin; Rubio Brand of Auranofin; SK&F D 39162; SK&F-39162; SmithKline Beecham Brand of Auranofin; Yamanouchi Brand of Auranofin; Auranofin Recordati Brand; Auranofin Robapharm Brand; Auranofin Rubio Brand; Auranofin Yamanouchi Brand; SK&F 39162; SK&F39162; Gold, (1-thio-beta-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)-

Networked: 377 relevant articles (45 outcomes, 78 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Messori, Luigi: 5 articles (08/2015 - 03/2008)
2.	Reed, Sharon L: 5 articles (01/2015 - 06/2012)
3.	Debnath, Anjan: 4 articles (02/2015 - 06/2012)
4.	Savarino, Andrea: 3 articles (10/2015 - 07/2011)
5.	Modesti, Alessandra: 3 articles (08/2015 - 05/2010)
6.	Magherini, Francesca: 3 articles (08/2015 - 05/2010)
7.	McKerrow, James H: 3 articles (02/2015 - 06/2012)
8.	Spitz, Douglas R: 3 articles (01/2015 - 10/2011)
9.	Andrade, Rosa M: 3 articles (01/2015 - 06/2012)
10.	Huang, Hongbiao: 3 articles (01/2015 - 07/2014)

Related Diseases

1.	Rheumatoid Arthritis 12/30/1983 - "We conclude that both drugs are effective in rheumatoid arthritis and that the lesser toxicity with auranofin will make it a valuable addition to our therapeutic armamentarium." 06/01/2010 - "Since dysregulation of TLRs can lead to severe systemic inflammatory and joint destructive process in rheumatoid arthritis, auranofin-mediated modulation of TLR activation may have therapeutic potential against such diseases. " 03/01/1984 - "Auranofin is safe and effective for short- and long-term treatment of patients with rheumatoid arthritis. " 12/07/1985 - "The present study evaluates the long-term efficacy of auranofin in 46 patients with active rheumatoid arthritis and attempts to delineate further the results of drug monitoring concerning adverse reactions. " 05/01/1984 - "While patients have demonstrated clinical remission of rheumatoid arthritis in response to auranofin therapy, radiological studies have been inconclusive regarding its effect on the occurrence or progression of erosive lesions. "
2.	Pain (Aches) 02/15/1988 - "The proportions of patients showing 50% or greater improvement in tender joints, swollen joints, activity index, severity of pain, general health rating, and erythrocyte sedimentation rate (ESR) were similar for both auranofin-treated and GST-treated patients who completed the 48-week trial. " 01/01/1986 - "Efficacy of auranofin was apparent by 3 months after the start of treatment, as evidenced by improvement over baseline in number of tender joints, severity of pain, and erythrocyte sedimentation rate. " 01/01/2000 - "A statistically significant benefit was observed for auranofin when compared to placebo for tender joint scores, pain, patient and physician global assessments and ESR. " 10/01/1986 - "Auranofin was superior to placebo in the clinical (p = 0.003), functional (p = 0.001), and global (p = 0.007) composites and trended similarly in the pain composite (p = 0.021). " 11/01/1983 - "Of 193 patients who received any treatment, the only important improvement identified for either auranofin or GST was for pain/tenderness scores. "
3.	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 01/01/1990 - "The authors describe the results of prospective multicenter Soviet-American placebo-controlled 6-month investigations concerned with assessment of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis (JRA). " 01/01/1990 - "[The evaluation of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis (the results of Soviet-American research)]." 08/01/1988 - "The safety and efficacy of auranofin in the long-term treatment of children with juvenile rheumatoid arthritis was investigated in an open study of 14 patients. " 08/01/1991 - "Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial." 01/01/1986 - "Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study."
4.	Asthma (Bronchial Asthma) 12/01/1991 - "We suggest that inhibition of bronchial hyperresponsiveness by auranofin is one of the mechanisms by which auranofin is effective against bronchial asthma." 07/01/1994 - "A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. " 12/01/1991 - "Recently, in Japan, auranofin (6 mg/day) has been demonstrated to be a useful treatment for patients with moderate to severe asthma in a double-blind clinical trial. " 08/01/1996 - "Therefore this study has demonstrated that auranofin is useful as a steroid-sparing agent in the treatment of chronic corticosteroid-dependent asthma." 01/01/1988 - "An open study of auranofin in the treatment of steroid-dependent asthma."
5.	Arthritis (Polyarthritis) 06/01/1994 - "Degree of improvement of arthritis was better in the GST group, but the number of improved patients was greater in the auranofin group. " 11/01/1995 - "In order to study the pharmacological action site of auranofin during the functional suppression of leukocytes, especially neutrophils, we investigated the influence of auranofin on the calcium-45 (45Ca2+) uptake into peripheral blood neutrophils and peritoneal resident macrophages isolated from normal and adjuvant-induced arthritis (AA) rats. " 09/01/2000 - "These models are illustrated by reanalyzing three data sets, foremost a set of binary time series on auranofin therapy against arthritis. " 08/01/1997 - "Sixty-five patients with onset of arthritis after the age of 60 yr were randomized to either auranofin 3 mg b.i.d. " 09/01/1988 - "[Clinical effectiveness and tolerance of auranofin in patients with chronic polyarthritis. "

Related Drugs and Biologics

1.	Gold
2.	Gold Sodium Thiomalate (Sodium Aurothiomalate)
3.	Auranofin (Ridaura)
4.	Azathioprine (Imuran)
5.	Hydroxychloroquine (Plaquenil)
6.	Methotrexate (Mexate)
7.	OM 89
8.	Histamine (Histamine Dihydrochloride)
9.	Penicillamine (Cuprimine)
10.	Sulfasalazine (Azulfidine)

Related Therapies and Procedures

1.	Injections
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Oral Administration
5.	Drug Repositioning